Exicure, Inc.

Healthcare · Biotechnology · United States

Last price 0.9348 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.12M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.